The mutant of Ras protein with serine to asparagine mutation at residue 17 (Ras-17N) is known to interfere with the signaling function of the wild-type Ras protein by sequestering its guanine-nucleotide exchange factors (GEFs). The similar mutant of another Ras family protein Rap1 (Rap1-17N) fails to effectively interfere with the interaction between the wild-type Rap1 and one of its GEFs, C3G, in vitro. In the present study, we have attempted to isolate Rap1 mutants with increased affinity for C3G using random mutagenesis and yeast two-hybrid screening. Based on the pattern of mutations found among these mutants, we could design a potent C3G-binder, named Rap1-AGE, harboring mutations in three sites (17A, 29G, and 117E). The association of Rap1-AGE with C3G in the cells was confirmed by co-immunoprecipitation experiments. The ability of Rap1-AGE to inhibit C3G-mediated Rap1-activation and cell spreading was also demonstrated. On the other hand, Rap1 activation mediated by two other GEFs, Epac and smgGDS, was not inhibited by Rap1-AGE. These results suggest that Rap1-AGE acts as a dominant interfering factor against C3G and serves as a useful tool in analyzing the roles of C3G-Rap1 signaling pathway in various biological processes.
Introduction
Rap1 was first identified as a transformation suppressor gene against the v-K-ras oncogene (Kitayama et al., 1989; reviewed in Noda, 1993) and was found to encode a member of the Ras family of small G proteins which shares about 50% identity with Ras proteins. Analogous to Ras, Rap1 is believed to serve as a molecular switch that is regulated by two other groups of factors, guanine-nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). GEFs stimulates the release of GDP from Rap1 thereby stimulating its association with GTP, while GAPs stimulate intrinsic GTPase activity of Rap1 thereby converting the active (GTP-bound) form of Rap1 to its inactive (GDPbound) form (Vetter and Wittinghofer, 2001 ). Several GEFs (Tanaka et al., 1994; de Rooij et al., 1998 de Rooij et al., , 1999 Kawasaki et al., 1998) and several GAPs (Rubinfeld et al., 1991; Mochizuki et al., 1999; Tsukamoto et al., 1999; Pak et al., 2001 ) acting on Rap1 have been identified.
When Rap1 was initially discovered as a transformation suppressor, two alternative mechanisms of its action were proposed (Kitayama et al., 1989) . One model, based on the structural similarity in their effector domains, postulated that Rap1 might antagonize Ras by competing for common targets or regulators. Second model proposed that Rap1 might transmit its own signals independent of Ras. Several lines of evidence support the latter model. First, subcellular localization of Rap1 seems to differ from Ras; Ras is enriched on the inner surface of the plasma membrane (Furth et al., 1982) , while Rap1 is abundant in Golgi apparatus as revealed by immunofluorescent staining of cultured cells (Beranger et al., 1991) . Consistent with this finding, when monitored by the fluorescence-resonance energy transfer technique, Rap1 activation seems to start from the perinuclear region, while Ras activation starts from the plasma membrane . Second, Rap1 is activated rapidly in response to a variety of extracellular stimuli including growth factors, hormones, and cytokines (reviewed in Zwartkruis et al., 1998; Bos et al., 2001; Stork, 2003) . Rap1 is also activated by some intracellular second messengers such as cAMP, diacylglycerol, and calcium, and in some cases, second messenger molecules directly bind and activate specific Rap1 GEFs (de Rooij et al., 1998; Kawasaki et al., 1998) . Third, many cytokines and growth factors promote integrin-dependent cell adhesion through activation of Rap1 (Caron et al., 2000; Katagiri et al., 2000; Reedquist et al., 2000) , and this activity of Rap1 is independent of Ras (reviewed in Bos et al., 2001; Kinbara et al., 2003) . Fourth, Rap1 was found to induce B-Raf-mediated ERK activation (Vossler et al., 1997; York et al., 1998) , although this may depend on the systems used . Fifth, several other proteins with no obvious relevance to Ras signaling have also been identified as downstream effectors of Rap1 in various types of cells (Serebriiskii et al., 1997; Zwartkruis et al., 1998; Tsygankova et al., 2001; Katagiri et al., 2003) . Yet other findings support antagonistic roles of Rap1 against Ras; Rap1 interferes with the ERK activation in fibroblasts (Cook et al., 1993) and the AMPA receptor trafficking (Zhu et al., 2002) , NMDA receptor activation (Imamura et al., 2003) , and enhancement of sodium current (Imamura et al., 2004) in neuronal cells that are stimulated by Ras. In short, Rap1 can transmit signals that are independent of Ras; a wide variety of upstream and downstream components may be involved in Rap1 signaling; and Rap1 may or may not counteract Ras depending on experimental systems employed.
One of the Rap1 GEFs, C3G, was first identified as a Crk SH3 domain-binding protein (Tanaka et al., 1994) . In addition to the proline-rich Crk-binding domain, C3G contains a CDC25 homology domain at its C-terminus. The CDC25 homology domain is responsible for promoting release of GDP from Rap1 (Gotoh et al., 1995) . Importance of the C3G-Rap1 signaling pathway for mammalian development has been demonstrated through the analysis of C3G-deficient mice. Mice lacking functional C3G died before E7.5 , and mice homozygous for a hypomorphic C3G allele died around E11.5 with vascular defects (Voss et al., 2003) . Experiments using embryo fibroblasts from C3G-deficient mice indicated that C3G-dependent Rap1 activation is required for adhesion and spreading of the cells. In addition, Rap1 is known to interact with several other GEFs including smgGDS that shows a wide substrate specificity (Yamamoto et al., 1990) , Epac which directly interacts with and being activated by cAMP (de Rooij et al., 1998) , and phospholipase C (PLC) epsilon which contains Rap1-binding domain (Song et al., 2001) . Thus, to better understand the roles of C3G-Rap1 pathway in the regulation of cell behavior and to elucidate how Rap1 regulates multiple signaling pathways in response to a wide variety of stimuli, reagents that specifically inhibit the molecular interaction between Rap1 and a particular GEF would be useful.
Dominant-negative mutants that interfere with the activities of the wild-type proteins are useful for elucidating their biological functions (Herskowitz, 1987; Feig, 1999) . In the case of Ras, a mutant with preferential affinity for GDP over GTP (Ras-17N) was found to have a versatile dominant-negative activity (Feig and Cooper, 1988) . Ras-17N forms stable complex with its GEFs (Chen et al., 1994) and inhibits the activation of the wild-type Ras by sequestering these GEFs. In the case of Rap1, however, the corresponding mutant (Rap1-17N) fails to efficiently inhibit the interaction between the wild-type Rap1 and C3G in vitro (van den Berghe et al., 1997) . Nevertheless, several papers have reported successful use of Rap1-17N in functional studies on Rap1 (Vossler et al., 1997; York et al., 1998; Schmitt and Stork, 2000) .
In the present study, we have obtained a series of novel Rap1 mutants exhibiting increased affinity for the catalytic domain of C3G by PCR-based random mutagenesis and two-hybrid screening. Here we report that Rap1-AGE, one of the potent C3G binders, inhibits C3G-mediated Rap1 activation and cell spreading in cultured cells.
Results
Interaction between Rap1-17N and C3G is hard to detect in yeast two-hybrid assay
The previous observation by van den Berghe et al. (1997) that the Rap1-17N mutant cannot titrate away C3G in vitro, prompted us to generate novel Rap1 mutants having increased affinity for C3G. To this end, we took advantage of the yeast two-hybrid assay as a means to readily detect association between two proteins. We first confirmed that the interaction between Ras-17N, the prototype dominant-negative mutant of small G proteins, in combination with one of its targets, RasGRF, could be detected in this assay (data not shown). Under the same conditions, the interaction between Rap1-17N or wild-type Rap1 and a fragment of C3G that contains its catalytic domain (C3Gct) was undetectable. We also failed to detect the interaction between Rap1-17N and the catalytic domains of other GEFs including smgGDS, Epac, and PLC epsilon (data not shown). These results indicate that this screening system yields virtually no background signals and should be useful in detecting Rap1 mutants with increased affinity for GEFs that is comparable to, or even greater than, the affinity between the control Ras-17N and RasGRF. These results also suggest that Rap1-17N has rather low affinity, if any, with the GEFs tested here at least under the experimental conditions we used.
Generation of Rap1 mutants with increased affinity for C3G
Having established the feasibility of the screening system, we employed a PCR-based random mutagenesis method to construct a Rap1 mutant library. The mutagenized cDNAs were transferred in-frame into the yeast expression vector containing the GAL4 DNAbinding domain sequences (pGBKT7). Using a C3Gct/ GAL4 activation domain fusion protein as a bait, we screened the mutant cDNA library (size: 3.3 Â 10 6 clones) by yeast two-hybrid assay ( Figure 1a ) and isolated 13 independent clones. The plasmids were recovered from the yeast clones, and the sequences of the Rap1 coding region determined ( Figure 1b) .
Amino acid substitutions were found at two to six (average 3.2) sites per clone. Although the sites of mutations were widely distributed (amino-acid positions 11-172), three regions with clustered mutations were found: amino-acid positions 14-17 (cluster 1), 28-32 (cluster 2), and 116-119 (cluster 3). These three regions coincide with, or closely apposed to, the domains responsible for guanine-nucleotide binding (G1, G2, and G4).
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To estimate relative strength of binding, we performed quantitative b-galactosidase (b-Gal) assay ( Figure 1c ). The M6 mutant harboring four substitutions (14I, 30G, 87R, and 117N) exhibited the strongest activity. Since we used PCR for mutagenesis, several of these mutants might have arisen from common ancestral mutants generated during amplification. It is also possible that some of these mutations do not contribute, or even be inhibitory, to the increased affinity for C3Gct. To test these possibilities, we generated seven mutants harboring single amino acid substitution in one of the three mutation cluster regions (14A, À17A, À29G, À30G, À32F, À117N, and À117E). None of these mutants, however, gave rise to positive colonies in the two-hybrid assay (data not shown). We then generated mutants harboring double or triple substitutions in various combinations and tested their C3G-binding activity by the quantitative b-Gal assay ( Figure 2 ). Combination of the 17A and 117E mutations consistently resulted in high b-Gal activity. The 29G mutation seems to have additional effects in conjunction with these mutations. Thus, we decided to use the triple mutant Rap1-17A29G117E (Rap1-AGE) for further investigations. Importantly, Rap1-AGE does not show the interaction with the catalytic domains of smgGDS, Epac, and PLC epsilon in yeast two-hybrid assay (data not shown).
Interaction between C3G and Rap1-AGE in mammalian cells
To test the ability of Rap1-AGE to bind C3G in mammalian cells, NIH3T3 cells were cotransfected with Myc-tagged C3Gct and HA-tagged Rap1-AGE, and the cell lysate was analysed by immunoprecipitation with anti-HA antibody followed by immunoblot detection with anti-Myc antibody. Strong binding of Rap1-AGE with C3Gct was detectable under these conditions, whereas the binding of Rap1-17N to C3Gct was much weaker (Figure 3a, lanes 4 and 3) . The results with Rap1 mutants generated by PCR-based random mutagenesis were expressed as GAL4 DNA-binding domain (BD) fusions, and a C-terminal fragment of C3G containing its catalytic domain (C3Gct) was expressed as GAL4 activation domain (AD) fusion in yeasts. Cotransformants were screened on SD selection plates. (b) Primary structure of Rap1 mutants selected by two-hybrid screening. Amino acid substitutions found in the mutants (M1-M13) with increased affinity for C3G are shown. The boxes G1-G5 indicate the regions involved in guanine-nucleotide binding (Sprang, 1997) . (c) Comparison of C3G-binding activities of Rap1 mutants. To estimate the relative strength of binding between C3G and each of the Rap1 mutants, b-Gal activity in the lysates of the yeasts harboring the C3G bait and the Rap1 mutant was determined. The data are presented as the ratios to the value obtained with the control vector Rap1 mutants dominantly inhibiting C3G function S Shi et al full-length C3G were even clearer (Figure 3b ). Hence, Rap1-AGE can strongly interact with C3G in mammalian cells.
Inhibition of C3G-mediated Rap1 activation by Rap1-AGE
Having confirmed the strong binding of Rap1-AGE with C3G in the cells, the next critical question was whether Rap1-AGE could dominantly suppress the ability of C3G to activate the wild-type Rap1. To address this question, we first employed the pull-down assay using the Rap1-binding domain of RalGDS (GST-RalGDS-RBD) (Franke et al., 1997; Zwartkruis et al., 1998) . In a control experiment, we confirmed that GTP-bound, active form of Rap1-AGE itself was not detectable in this assay (data not shown). We also employed a constitutively active form of C3G (C3G-CAAX: full-length C3G fused with the C-terminal CAAX motif of K-Ras), as an activator of Rap1 to facilitate the detection of inhibitory effects in this assay. When C3G-CAAX was expressed in HEK293 cells, robust activation of endogenous Rap1 was detected ( Figure 4 , lane 2). When Rap1-AGE was coexpressed, substantial decrease in the C3G-CAAX-mediated Rap1 activation was observed, despite that the level of Rap1-AGE expression was not very high ( Figure 4, lane 4) . Rap1-17N showed a milder effect in this assay (Figure 4 , lane 3). These data indicate that Rap1-AGE can dominantly inhibit Rap1 activation mediated by C3G-CAAX.
Inhibition of C3G-mediated cell spreading by Rap1-AGE
A previous study using C3G-deficient cells indicated that C3G-dependent Rap1 activation is important for adhesion and spreading of mouse embryo fibroblasts (Ohba et al., 2001) . We also found that C3G-CAAX induces spreading of HEK293 cells on tissue culture dish coated with collagen type I (Figure 5a and b, bar 2) . Although Rap1-63E, an constitutively active mutant of Rap1 (Kitayama et al., 1990) , was effective in this assay (Figure 5b , bar 5), the effects of C3G-CAAX and Rap1-63E were not additive ( Figure 5b , bars 2, 5, and 6). Moreover, Rap1-AGE significantly suppressed the C3G-CAAX-mediated cell spreading (Figure 5b , bars 2 and 8), and this effect was dose dependent (Figure 5c ). These findings are consistent with the known epistatic relationship between C3G and Rap1 (i.e. C3G activates Rap1) and support the idea that Rap1-AGE may be useful in probing biological functions of this pathway. Interestingly, Rap1-17N also suppressed the C3G-CAAX-mediated cell spreading to some extent (Figure 5b, bar 10) . 
Inhibition of isoproterenol-induced Rap1 activation in HEK293 cells by Rap1-AGE
Involvement of Rap1 in signaling from heterotrimeric G proteins has been demonstrated (Bos et al., 2001) . One of the well-characterized model systems in which Ga s has been linked to the C3G-Rap1 signaling pathway is the activation of b 2 -adrenergic receptor by the specific agonist isoproterenol (Schmitt and Stork, 2000) . After treatment of HEK293 cells with 10 mM isoproterenol, increase in the level of GTP-bound Rap1 (i.e. activated endogenous Rap1) could be detected within 3 min ( Figure 6 , lane 2). This activation was suppressed when Rap1-AGE was expressed ( Figure 6 , lane 3). Hence, Rap1-AGE seems to be useful also in probing the roles of the endogenous C3G-Rap1 pathway in various physiological and pharmacological events. Rap1-17N was also effective to some extent in this system ( Figure 6 , lane 4).
Target selectivity of Rap1-AGE in mammalian cells
The interaction of Rap1-AGE with C3G seemed to be selective among the several Rap1 GEFs we tested in the yeast two-hybrid assay (data not shown). This was confirmed in mammalian (HEK293) cells with two GEFs (Figure 7) . First, the Rap1 activation by Epac overexpression (Figure 7a, lane2) was not inhibited by Rap1-17N or Rap1-AGE (Figure 7a, lanes 3 and 4) . Second, the Rap1 activation by overexpression of the Myc-tagged catalytic domain of smgGDS (smgGDSct) (Figure 7b , lane 2) was not effectively inhibited by Rap1-17N and Rap1-AGE (Figure 7b, lanes 3 and 4) . Hence, C3G seems to be a better target for Rap1-AGE than Epac and smgGDS.
Discussion
The present study has demonstrated that dominantnegative mutants of a small G protein can be isolated by random mutagenesis followed by two-hybrid screening using one of its GEFs as a bait. Our data also indicate the advantage of using PCR-based mutagenesis, which apparently gives rise to families of mutants harboring accumulated mutations and exhibiting favorable property in a progressive manner. Indeed, the potent triple mutant, Rap1-AGE, could not be generated without the sequence information from the collection of related mutants. With minor modifications, this approach can Three regions with clustered mutations that cooperatively help increasing the affinity of Rap1 to C3G were found: residues 14-17 (cluster 1), 28-32 (cluster 2), and 116-119 (cluster 3). In Ras, the side chains of residues 28, 116, 117, and 119 are interacting with the guanine base; the side chain of residue 117 and the backbone of residue 29 are interacting with the ribose; and the backbone NH groups of residues 14-17 and the side chain of residue 16 are interacting with the b-phosphate (Milburn et al., 1990; Sprang, 1997) . The side chain of residue 17 also participates in coordination of Mg 2 þ . Provided the strong structural similarity between Ras and Rap1 in these regions, amino acid substitutions in the corresponding regions of Rap1 may affect the affinity of this molecule for guanine nucleotides. Actual molecular mechanisms of the dominant-negative actions of Rap1-AGE, however, remain to be elucidated. Whether Rap1-AGE exhibits preferential affinity for GDP over GTP, as in the case of Ras-17N, is among the important questions to be addressed in future studies.
It is believed that Ras interacts with its GEFs (e.g. Sos) through at least three regions: switch I (residues 25-40), switch II (residues 57-75), and the residues 100-110 (van den Berghe et al., 1999) . Characterization of the Rap1 mutants harboring substitutions in the corresponding regions indicated that leucine at residue 70 of Rap1 was particularly important for association with C3G (van den Berghe et al., 1999) . It remains to be clarified, however, whether simple replacement of residue 70 to another amino acid is sufficient to convert Rap1 to a dominant-negative mutant inhibiting C3G signaling. Among the mutants obtained in our initial screening (Figure 1) , three clones have substitutions in the switch II region (the 66T mutation in M13, 71F mutation in M4, and 73R mutation in M12). We did not characterize the effects of these mutations in detail, since clustered mutations were not found in the switch II region. This, however, does not necessarily mean that mutations in the switch II region are ineffective.
In several previous studies, Rap1-17N has been shown to act as a dominant-negative mutant (Vossler et al., 1997; York et al., 1998; Schmitt and Stork, 2000) . The mechanism of its inhibitory effects, however, is still unclear. We also observed in this study that Rap1-17N could inhibit some of the biological activities of C3G (Figures 5 and 6 ), even though we failed to detect its increased affinity for C3G. Two explanations are possible. First, Rap1-17N may exert its dominantnegative effects without tightly binding to its target. Second, Rap1-17N may exert its (apparently dominantnegative) effects through interaction with other molecule(s). Our data with Epac and smgGDS (Figure 7 ) seem to indicate that not only Rap1-AGE but also Rap1-17N inhibits C3G in a selective fashion. Hence, the exact mechanism by which Rap1-17N exerts its biological activity remains a mystery at present.
In theory, truncated forms of C3G may also act as dominant-negative factors for C3G signaling. Indeed, an N-terminal fragment of C3G has been used to inhibit wild-type C3G (Gotoh et al., 1995; Schmitt and Stork, 2000) . This type of reagents, however, may interfere Figure 6 Inhibition of isoproterenol-induced Rap1 activation by Rap1-AGE. HEK293 cells were transfected with the plasmids indicated on the top. After 24 h, the cells were serum starved for 24 h, and then 10 mM isopreterenol was added. After 3 min, cells were harvested, lysed, and the lysates were subjected to pull-down assay to detect active Rap1. The ratio of band intensity (pull-down/ total), which represents normalized, relative level of activation, is presented under the middle panel. Note that isoproterenol activates endogenous Rap1 (lane 2) and that Rap1-AGE suppresses this effect significantly (lane 3). The upper part of the lower panel shows the slowly migrating, exogenous Rap1 (HA tagged) bands Figure 7 Effects of Rap1-AGE on Epac-induced (a) or smgGDSinduced (b) Rap1 activation. HEK293 cells were cotransfected with plasmids expressing indicated proteins. After 24 h, the cells were harvested, lysed, and the lysates were subjected to pull-down assay. The ratio of band intensity (pull-down/total), which represents normalized, relative level of activation, is presented under the middle panel. Note that Epac and smgGDS activated endogenous Rap1 (lane 2) and that both Rap1-17N (lane 3) and Rap1-AGE (lane 4) showed little effects on this activation Rap1 mutants dominantly inhibiting C3G function S Shi et al with the functions of an upstream component(s) in the signaling cascade. Since Crk, an activator of C3G, is known to interact with multiple proteins (Feller, 2001) , effects of the C3G fragment on the other downstream pathways should also be analysed before drawing conclusion that the action of C3G is indeed specifically inhibited. Similar arguments can be made on Rap1-AGE. Since C3G probably transmits its signals through multiple pathways (Ohba et al., 2000) , Rap1-AGE may also interfere with the other pathways besides Rap1 pathway, and it is important to keep this in mind when interpreting the biological data obtained using this mutant. Nevertheless, selective affinity of Rap1-AGE for C3G is an important advantage of this mutant and indicates its potential value in classifying Rap1-mediated signaling events into two groups, C3G dependent and C3G independent. The results of model experiment with the isoproterenol-dependent Rap1 activation ( Figure 6 ) support the feasibility of such experiments.
Recent studies indicate that Rap1 is involved in integrin-mediated cell adhesion (Bos et al., 2001; Kinbara et al., 2003) . In mouse embryo fibroblasts, C3G-dependent Rap1 activation is required for cell adhesion and cell spreading . C3G is also required for the formation and stabilization of integrin b 1 -positive focal adhesions (Voss et al., 2003) . In HeLa cells SPA-1, one of the RapGAPs, blocked the attachment of cells to fibronectin-coated plates (Tsukamoto et al., 1999) . In the present study, we showed that cell spreading in HEK293 cells was suppressed by expressing Rap1-AGE. Since HEK293 cells are easy to handle and highly susceptible to DNA transfection, the present experimental system should be useful for determining biological activities of Rap1 in future studies.
In conclusion, we have isolated a series of Rap1 mutants with increased affinity for C3G. The most potent mutant, Rap1-AGE, may serve as a useful tool for inhibiting C3G-mediated Rap1 activation.
Materials and methods

Cells and yeast strains
NIH3T3 cells and human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin1 mg/ml). Yeast AH109 and Y187 strains were purchased from Clontech.
Antibodies
Anti-Rap1, anti-Myc, and anti-Flag antibodies were purchased from Transduction Labratories, Clontech, and Stratagene, respectively. Anti-HA and anti-Epac antibodies were purchased from Santa Cruz.
Plasmids
The plasmids used for yeast two-hybrid assay, pGBKT7 and pGADT7, were purchased from Clontech. The mammalian expression vectors, pCMV-Myc and pCMV-HA, were purchased from Clontech and pcDNA3.1 and pEF6A from Invitrogen. The pEGFP-C3 vector was purchased from Clontech. The pCMV-Flag vector was constructed by replacing the short SacI/EcoRI fragment of pCMV-Myc with the SacI/EcoRI digested fragment, which was produced by PCR using pCMV-Myc as a template and the oligonucleotide primers, 5 0 -GCAGAGCTCGTTTAGTGAACCG-3 0 and 5 0 -TTTGAATTCGCTTGTCATCGTCATCCTTGTAATCCAT GGTGGGCCCGCGG-3 0 . pcDNA3.1-CAAX was constructed by inserting a fragment of K-Ras encoding CAAX motif (C-terminal 20 residues) using the XhoI and ApaI sites of pcDNA3.1. For yeast two-hybrid assays, a cDNA fragment encoding either Rap1, Rap1 mutants, or Ras-17N (all lacking their C-terminal three residues) was inserted into pGBKT7 to express the protein whose N-terminus is fused with GAL4 DNA-binding domain. A cDNA fragment encoding the catalytic domain of either human C3G (residues 831-1077), smgGDS (residues 111-346), Epac (residues 556-882), PLC epsilon (residues 379-742), or mouse RasGRF (residues 1015-1260) was inserted into pGADT7 to express the protein whose N-terminus is fused with GAL4 activation domain. To express epitope-tagged Rap1 proteins in mammalian cells, a cDNA fragment encoding Rap1, Rap1-17N, or Rap1-AGE was inserted into pCMV-HA or pCMV-Flag. To express Rap1 proteins without a tag, a cDNA fragment containing the entire coding region (including the termination codon) of either Rap1, Rap1-17N, Rap1-63E, or Rap1-AGE was inserted into pEF6A. pcDNA3.1-C3G-CAAX was constructed by inserting a cDNA fragment encoding mouse C3G lacking its termination codon into pcDNA3.1-CAAX vector. To express Myctagged C3G proteins, a cDNA fragment encoding either the catalytic domain of mouse C3G (residues 839-1087), C3G, or C3G-CAAX was inserted into pCMV-Myc. To express Myctagged smgGDSct proteins, a cDNA fragment encoding the catalytic domain of human smgGDS (residues 111-346) was inserted into pCMV-Myc.
Construction of Rap1 mutants and yeast two-hybrid screening
A cDNA fragment containing Rap1 coding region except Cterminal three residues was subcloned into the EcoRI/XhoI sites of pBluescript SK ( þ ) (Stratagene). Mutation was introduced into this plasmid using Diversify PCR Random Mutagenesis kit (Clontech). PCR was carried out following the manufacturer's instructions using the buffer condition 5 and the primer set 5 0 -TTTTGAATTCATGCGTGAGTACAAG CT-3 0 and 5 0 -TTCTCGAGCTAACATGATTTCTTTTTAG GC-3 0 . After digestion of the PCR products with EcoRI and XhoI, the fragments were ligated into the EcoRI/SalI sites of pGBKT7. The ligation products were then transformed into DH5a and the number of independent colonies was scored. The plasmids were extracted from a pool of 2.6 Â 10 5 independent colonies and used as a Rap1 mutant library. The pGBKT7-Rap1 mutant library was transformed into the Saccharomyces cerevisiae strain AH109 harboring pGADT7-C3Gct. The transformants were selected on SD plates lacking leucine, tryptphan histidine, and adenine. The plasmids were recovered from individual colonies and sequenced using BigDye terminator sequencing kit (Applied Biosystems). Rap1 mutants harboring double or triple substitutions were constructed by ligating appropriate portions of the mutant cDNAs obtained in the original library screening, and when necessary, additional mutations were introduced using Quick Change site-directed mutagenesis kit (Stratagene). Rap1-AGE mutant was made by introducing 17A mutation into the original mutant clone M3 by site-directed mutagenesis.
